INR 13.38
(0.15%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.06 Billion INR | -9.97% |
2022 | 1.14 Billion INR | -21.84% |
2021 | 618.21 Million INR | 14.01% |
2020 | 469.62 Million INR | 32.14% |
2019 | 521.2 Million INR | 70.57% |
2018 | 174.02 Million INR | -6.63% |
2017 | -72.83 Million INR | 134.49% |
2016 | -3.12 Billion INR | 36.47% |
2015 | -1.44 Billion INR | -118.41% |
2014 | -682.45 Million INR | -864.88% |
2013 | -160.57 Million INR | -599.72% |
2012 | -109.85 Million INR | 0.0% |
2010 | 1.32 Billion INR | 41.27% |
2009 | 934.63 Million INR | 7.7% |
2008 | 867.67 Million INR | 14.87% |
2007 | 755.47 Million INR | 48.56% |
2006 | 508.52 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 32.2 Million INR | -94.73% |
2023 Q4 | 144.86 Million INR | 222.82% |
2023 Q1 | 240.28 Million INR | 68.82% |
2023 Q2 | 142.93 Million INR | -40.51% |
2023 Q3 | 44.87 Million INR | -68.61% |
2023 FY | - INR | -9.97% |
2022 Q3 | 210.95 Million INR | 76.9% |
2022 FY | - INR | -21.84% |
2022 Q4 | 142.33 Million INR | -32.53% |
2022 Q1 | 66.33 Million INR | -65.26% |
2022 Q2 | 119.25 Million INR | 79.78% |
2021 Q4 | 190.92 Million INR | 28.59% |
2021 Q1 | 166.99 Million INR | 38.12% |
2021 FY | - INR | 14.01% |
2021 Q2 | 183.09 Million INR | 9.64% |
2021 Q3 | 148.47 Million INR | -18.91% |
2020 Q4 | 120.9 Million INR | -35.98% |
2020 FY | - INR | 32.14% |
2020 Q2 | 170.37 Million INR | 36.69% |
2020 Q3 | 188.86 Million INR | 10.85% |
2020 Q1 | 124.64 Million INR | -17.47% |
2019 Q2 | 86.18 Million INR | 28.67% |
2019 Q4 | 151.01 Million INR | -1.62% |
2019 Q3 | 153.51 Million INR | 78.12% |
2019 FY | - INR | 70.57% |
2019 Q1 | 66.98 Million INR | 976.35% |
2018 FY | - INR | -6.63% |
2018 Q4 | 6.22 Million INR | 27.57% |
2018 Q2 | 44.96 Million INR | -70.07% |
2018 Q1 | 150.25 Million INR | -5.85% |
2018 Q3 | 4.87 Million INR | -89.15% |
2017 Q3 | 95.37 Million INR | 0.0% |
2017 Q1 | -29.28 Million INR | 95.96% |
2017 FY | - INR | 134.49% |
2017 Q4 | 159.59 Million INR | 67.34% |
2016 Q3 | -1.73 Billion INR | -212.91% |
2016 FY | - INR | 36.47% |
2016 Q1 | -111.49 Million INR | 89.59% |
2016 Q2 | -553.56 Million INR | -396.51% |
2016 Q4 | -725.11 Million INR | 58.14% |
2015 Q2 | -75.66 Million INR | 49.1% |
2015 Q4 | -1.07 Billion INR | -742.49% |
2015 FY | - INR | -118.41% |
2015 Q3 | -127.07 Million INR | -67.93% |
2015 Q1 | -148.65 Million INR | 53.96% |
2014 Q3 | -324.5 Million INR | -409.95% |
2014 Q2 | -63.63 Million INR | -2.68% |
2014 Q1 | -61.97 Million INR | -433.95% |
2014 FY | - INR | -864.88% |
2014 Q4 | -322.88 Million INR | 0.5% |
2013 Q3 | -13.12 Million INR | 88.2% |
2013 Q4 | 18.55 Million INR | 241.43% |
2013 Q2 | -111.18 Million INR | -11.58% |
2013 FY | - INR | -599.72% |
2013 Q1 | -99.64 Million INR | 16.37% |
2012 Q4 | -119.14 Million INR | -57.08% |
2012 Q3 | -75.85 Million INR | -177.03% |
2012 FY | - INR | 0.0% |
2012 Q1 | - INR | 0.0% |
2012 Q2 | 98.46 Million INR | 0.0% |
2010 FY | - INR | 41.27% |
2009 FY | - INR | 7.7% |
2008 FY | - INR | 14.87% |
2007 FY | - INR | 48.56% |
2006 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Hester Biosciences Limited | 539.47 Million INR | -97.428% |
Albert David Limited | 1.04 Billion INR | -1.879% |
Alembic Limited | 1.11 Billion INR | 4.593% |
Alkem Laboratories Limited | 24.19 Billion INR | 95.598% |
Alembic Pharmaceuticals Limited | 9.61 Billion INR | 88.925% |
Bafna Pharmaceuticals Limited | 114.58 Million INR | -829.515% |
Bajaj HealthCare Limited | 406.23 Million INR | -162.178% |
FDC Limited | 3.38 Billion INR | 68.539% |
Glenmark Life Sciences Limited | 6.86 Billion INR | 84.481% |
Gufic Biosciences Limited | 1.48 Billion INR | 28.06% |
Hikal Limited | 2.69 Billion INR | 60.439% |
Ind-Swift Laboratories Limited | 6.86 Billion INR | 84.478% |
Innova Captab Limited | 1.66 Billion INR | 36.159% |
Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -229.273% |
Jubilant Pharmova Limited | 8 Billion INR | 86.697% |
Kilitch Drugs (India) Limited | 287.42 Million INR | -270.554% |
Laurus Labs Limited | 8 Billion INR | 86.697% |
Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 20.714% |
Lupin Limited | 36.96 Billion INR | 97.119% |
Mangalam Drugs & Organics Limited | 174.94 Million INR | -508.797% |
Medico Remedies Limited | 129.09 Million INR | -725.031% |
Morepen Laboratories Limited | 1.72 Billion INR | 38.291% |
Nectar Lifesciences Limited | 1.53 Billion INR | 30.641% |
Orchid Pharma Limited | 1.41 Billion INR | 24.952% |
Procter & Gamble Health Limited | 3.07 Billion INR | 65.357% |
RPG Life Sciences Limited | 1.28 Billion INR | 16.889% |
Solara Active Pharma Sciences Limited | -2.82 Billion INR | 137.743% |
Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.23% |
Suven Pharmaceuticals Limited | 4.67 Billion INR | 77.228% |
Themis Medicare Limited | 562.6 Million INR | -89.309% |
Unichem Laboratories Limited | 742.35 Million INR | -43.471% |
Vaishali Pharma Limited | 31.71 Million INR | -3258.664% |
Venus Remedies Limited | 711.8 Million INR | -49.63% |
Wanbury Limited | 985.49 Million INR | -8.075% |
Windlas Biotech Limited | 781.72 Million INR | -36.246% |
ZIM Laboratories Limited | 462.09 Million INR | -130.485% |
Ipca Laboratories Limited | 13.29 Billion INR | 91.992% |
Aarti Drugs Limited | 3.24 Billion INR | 67.215% |
Aarti Pharmalabs Limited | 3.9 Billion INR | 72.756% |
Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -8095.337% |
Brooks Laboratories Limited | 41.72 Million INR | -2452.401% |
Eris Lifesciences Limited | 6.98 Billion INR | 84.755% |
IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 59.14% |
Sigachi Industries Limited | 883.39 Million INR | -20.565% |
Sakar Healthcare Limited | 393.26 Million INR | -170.824% |
Aurobindo Pharma Limited | 61.78 Billion INR | 98.276% |
Divi's Laboratories Limited | 25.43 Billion INR | 95.812% |
AstraZeneca Pharma India Limited | 2.35 Billion INR | 54.809% |
Mankind Pharma Limited | 28.09 Billion INR | 96.209% |
Sequent Scientific Limited | 549.8 Million INR | -93.719% |
Neuland Laboratories Limited | 4.74 Billion INR | 77.569% |
J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 88.59% |
Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 90.611% |
Zydus Lifesciences Limited | 56.22 Billion INR | 98.106% |
Amrutanjan Health Care Limited | 681.59 Million INR | -56.261% |
Wockhardt Limited | 1.08 Billion INR | 1.383% |
Bal Pharma Limited | 345.59 Million INR | -208.186% |
Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.793% |
Bliss GVS Pharma Limited | 1.47 Billion INR | 27.989% |
Par Drugs and Chemicals Limited | 228.17 Million INR | -366.778% |
Caplin Point Laboratories Limited | 6.18 Billion INR | 82.777% |
Shilpa Medicare Limited | 2.58 Billion INR | 58.846% |
Valiant Laboratories Limited | 12.73 Million INR | -8260.672% |
Ajanta Pharma Limited | 12.56 Billion INR | 91.524% |
Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -2258.167% |
Granules India Limited | 8.6 Billion INR | 87.621% |
Medicamen Biotech Limited | 245.66 Million INR | -333.553% |
Syncom Formulations (India) Limited | 430.27 Million INR | -147.531% |
Piramal Enterprises Limited | -3.86 Billion INR | 127.585% |
Torrent Pharmaceuticals Limited | 35 Billion INR | 96.958% |
NATCO Pharma Limited | 18.79 Billion INR | 94.333% |
Suven Life Sciences Limited | -992.78 Million INR | 207.281% |
Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1387.447% |
Strides Pharma Science Limited | 3.76 Billion INR | 71.709% |
Indoco Remedies Limited | 2.64 Billion INR | 59.764% |
Alpa Laboratories Limited | 229.96 Million INR | -363.151% |
Lasa Supergenerics Limited | -65.08 Million INR | 1736.549% |
Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 128.543% |